Differentiation induction therapy with all-trans retinoic acid (ATRA) in a patient with secondary 11q23 leukemia

J Pediatr Hematol Oncol. 1996 Nov;18(4):405-8. doi: 10.1097/00043426-199611000-00015.

Abstract

Purpose: Frequently recurrent leukemia is encountered in childhood and is usually resistant to multidrug therapy. We evaluated the efficacy of differentiation induction therapy in a child with leukemia.

Patient and methods: We administered all-trans retinoic acid (ATRA) alone, and then a combination of low-dose 1-beta-D-arabinofuranosylcytosine (Ara-C), to a 7-year-old boy who had leukemia secondary to etoposide with chromosomal abnormality 11q23.

Results: The patient exhibited a good response to ATRA and had a complete remission after combination therapy of ATRA and low-dose Ara-C.

Conclusion: Differentiation induction therapy with ATRA was effective in treating a patient with recurrence of leukemia without t(15;17) translocation, and which is resistant to conventional cytotoxic treatment.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Child
  • Chromosome Aberrations
  • Chromosome Disorders
  • Chromosomes, Human, Pair 11
  • Cytarabine / administration & dosage
  • Drug Resistance, Multiple
  • Etoposide / administration & dosage
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Male
  • Translocation, Genetic
  • Tretinoin / therapeutic use*

Substances

  • Cytarabine
  • Tretinoin
  • Etoposide